Medesis Pharma SA (ALMDP) - Total Assets
Based on the latest financial reports, Medesis Pharma SA (ALMDP) holds total assets worth €2.11 Million EUR (≈ $2.46 Million USD) as of June 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see ALMDP cash flow conversion for how efficiently the company converts equity into cash flow.
Medesis Pharma SA - Total Assets Trend (2018–2023)
This chart illustrates how Medesis Pharma SA's total assets have evolved over time, based on quarterly financial data. See Medesis Pharma SA (ALMDP) stock price for real-time trading data and today's change.
Medesis Pharma SA - Asset Composition Analysis
Current Asset Composition (December 2023)
Medesis Pharma SA's total assets of €2.11 Million consist of 79.5% current assets and 20.6% non-current assets. Explore Medesis Pharma SA short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 2.2% |
| Accounts Receivable | €467.70K | 24.3% |
| Inventory | €164.62K | 8.6% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €198.97K | 10.3% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2018–2023)
This chart illustrates how Medesis Pharma SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Medesis Pharma SA's current assets represent 79.5% of total assets in 2023, an increase from 27.1% in 2018.
- Cash Position: Cash and equivalents constituted 2.2% of total assets in 2023, down from 5.9% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, a decrease from 71.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 24.3% of total assets.
Medesis Pharma SA Competitors by Total Assets
Key competitors of Medesis Pharma SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
ABCELLERA BIOLOGICS
F:8QQ
|
Germany | €1.31 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥7.07 Billion |
Medesis Pharma SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.46 | 0.41 | 0.77 |
| Quick Ratio | 0.41 | 0.36 | 0.66 |
| Cash Ratio | 0.00 | 0.00 | 0.12 |
| Working Capital | €-2.07 Million | €-1.87 Million | €-99.00K |
Medesis Pharma SA - Advanced Valuation Insights
This section examines the relationship between Medesis Pharma SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 108.23 |
| Latest Market Cap to Assets Ratio | 0.94 |
| Asset Growth Rate (YoY) | 0.6% |
| Total Assets | €1.93 Million |
| Market Capitalization | $1.80 Million USD |
Valuation Analysis
Near Book Valuation: The market values Medesis Pharma SA's assets close to their book value (0.94x), suggesting investors view the company's assets at approximately fair value.
Positive Asset Growth: Medesis Pharma SA's assets grew by 0.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Medesis Pharma SA (2018–2023)
The table below shows the annual total assets of Medesis Pharma SA from 2018 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | €1.93 Million ≈ $2.25 Million |
+0.56% |
| 2022-12-31 | €1.92 Million ≈ $2.24 Million |
-55.72% |
| 2021-12-31 | €4.33 Million ≈ $5.06 Million |
+416.33% |
| 2020-12-31 | €837.91K ≈ $979.61K |
+17.35% |
| 2019-12-31 | €714.00K ≈ $834.74K |
-56.03% |
| 2018-12-31 | €1.62 Million ≈ $1.90 Million |
-- |
About Medesis Pharma SA
Medesis Pharma S.A. operates as a biopharmaceutical company. The company's products include NanoLithium (NP03) for the treatment of Alzheimer's disease; NanosiRNA HD and NanoP42T to treat Huntington's disease; NanoLithium for the prevention and treatment of psychiatric disorders; NanoManganese (NP02), a radiation protection drug; and NU01 plutonium decorporation and NU02 cesium decorporation nucl… Read more